Literature DB >> 23880286

Benznidazole treatment in chronic children infected with Trypanosoma cruzi: serological and molecular follow-up of patients and identification of Discrete Typing Units.

M M Monje Rumi1, C Pérez Brandán, J F Gil, A M Alberti D'Amato, P G Ragone, J J Lauthier, N Tomasini, R O Cimino, V Orellana, C D Lacunza, J R Nasser, M A Basombrío, P Diosque.   

Abstract

A total of 221 children from two rural settlements in Northeast Argentina were examined for T. cruzi infection. Blood samples were taken for serology tests and PCR assays. In addition, T. cruzi Discrete Typing Units (DTUs) were determined by hybridization with specific DNA probes of the minicircle hypervariable regions (mHVR). Serological results indicated that 26% (57/215) were reactive against T. cruzi antigens. PCR analyses were performed on seropositive samples showing presence of parasite DNA in 31 out of 53 samples (58.5%). All seropositive children underwent specific chemotherapy with Benznidazole (5mg/kg/day) for a period of two months and were monitored two and five years after treatment. Overall the treatment was well tolerated and low side effects were observed. Serological conversion was observed at two years post -treatment in one child form Pampa Ávila and at five years in two children from Tres Estacas. However, at the end of the follow-up period, T. cruzi DNA could not be detected by PCR in samples from treated children, except in two cases. In addition, the results of hybridizations with specific DNA probes showed that DTU TcV was detected in 68% (21/31), TcVI in 7% (2/31) and TcV/VI in 3% (1/31) of the samples. Altogether, results of the follow-up of treated children showed a low rate of seroconversion; however trend toward seroconversion was evident at five years post-treatment. On the other hand, detection of T. cruzi DNA by PCR significantly decreased after Benznidazole treatment. The existence of data regarding serological and molecular follow-ups from controlled studies in the Chaco Region will be important for future treatment efforts against T. cruzi infection in this region. The results obtained in the present study represent a contribution in this regard.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Benznidazole; Chagas disease; DTUs; Hybridization; PCR; Serology

Mesh:

Substances:

Year:  2013        PMID: 23880286     DOI: 10.1016/j.actatropica.2013.07.003

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  8 in total

Review 1.  Chagas Disease in the United States: a Public Health Approach.

Authors:  Caryn Bern; Louisa A Messenger; Jeffrey D Whitman; James H Maguire
Journal:  Clin Microbiol Rev       Date:  2019-11-27       Impact factor: 26.132

2.  TcTASV Antigens of Trypanosoma cruzi: Utility for Diagnosis and High Accuracy as Biomarkers of Treatment Efficacy in Pediatric Patients.

Authors:  Noelia Floridia-Yapur; Mercedes Monje-Rumi; Paula Ragone; Juan J Lauthier; Nicolás Tomasini; Anahí Alberti D'Amato; Patricio Diosque; Rubén Cimino; José F Gil; Daniel O Sanchez; Julio R Nasser; Valeria Tekiel
Journal:  Am J Trop Med Hyg       Date:  2019-11       Impact factor: 2.345

Review 3.  Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.

Authors:  Yanina Sguassero; Cristina B Cuesta; Karen N Roberts; Elizabeth Hicks; Daniel Comandé; Agustín Ciapponi; Sergio Sosa-Estani
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

4.  Experimental evidence of biological interactions among different isolates of Trypanosoma cruzi from the Chaco Region.

Authors:  Paula G Ragone; Cecilia Pérez Brandán; Mercedes Monje Rumi; Nicolás Tomasini; Juan J Lauthier; Rubén O Cimino; Alejandro Uncos; Federico Ramos; Anahí M Alberti D'Amato; Miguel A Basombrío; Patricio Diosque
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

5.  Improving access to Chagas disease diagnosis and etiologic treatment in remote rural communities of the Argentine Chaco through strengthened primary health care and broad social participation.

Authors:  Paula Sartor; Ivana Colaianni; M Victoria Cardinal; Jacqueline Bua; Héctor Freilij; Ricardo E Gürtler
Journal:  PLoS Negl Trop Dis       Date:  2017-02-13

Review 6.  Course of serological tests in treated subjects with chronic Trypanosoma cruzi infection: A systematic review and meta-analysis of individual participant data.

Authors:  Yanina Sguassero; Karen N Roberts; Guillermina B Harvey; Daniel Comandé; Agustín Ciapponi; Cristina B Cuesta; Camila Aguiar; Ana M de Castro; Emmaría Danesi; Ana L de Andrade; Marta de Lana; Josep M Escribà; Diana L Fabbro; Cloé D Fernandes; María Flores-Chávez; Alejandro M Hasslocher-Moreno; Yves Jackson; Carlos D Lacunza; Girley F Machado-de-Assis; Marisel Maldonado; Wendell S F Meira; Israel Molina; María M Monje-Rumi; Catalina Muñoz-San Martín; Laura Murcia; Cleudson Nery de Castro; Olga Sánchez Negrette; Manuel Segovia; Celeste A N Silveira; Aldo Solari; Mário Steindel; Mirtha L Streiger; Ninfa Vera de Bilbao; Inés Zulantay; Sergio Sosa-Estani
Journal:  Int J Infect Dis       Date:  2018-06-04       Impact factor: 3.623

7.  Elucidating diversity in the class composition of the minicircle hypervariable region of Trypanosoma cruzi: New perspectives on typing and kDNA inheritance.

Authors:  Fanny Rusman; Nicolás Tomasini; Noelia-Floridia Yapur; Andrea F Puebla; Paula G Ragone; Patricio Diosque
Journal:  PLoS Negl Trop Dis       Date:  2019-06-27

8.  Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis.

Authors:  Clara Crespillo-Andújar; Emmanuele Venanzi-Rullo; Rogelio López-Vélez; Begoña Monge-Maillo; Francesca Norman; Ana López-Polín; José A Pérez-Molina
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.228

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.